Research
Hormonal
Tirzepatide has demonstrated significant body weight reductions in individuals with obesity but not diabetes.
Tirzepatide may be beneficial for weight management in patients with obesity.
StrongSupportsmedium confidence
Tirzepatide has demonstrated significant body weight reductions in individuals with obesity but not diabetes.
Why this rating
Based on clinical trial data.
Source
Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data
Ronald Goldenberg et al. · Current Opinion in Cardiology · 2023
reviewCited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →